candooman

candooman
Send Message
View as an RSS Feed
  • Midday Gainers / Losers  [View news story]
    ATHX is negotiating with the FDA on a new Ph 3 trial to show it works when applied between 16 and 36 hours after a stroke. Data already showed it is effective when treatment is applied between 24 and 36 hours. Data from the previous Trial showed that it hardly works beyond 36 hours. The original Trial time was 24 to 36 but for lack of patients, was amended to extend to 48 hrs (big mistake).

    The rise of the stock could be the anticipation of an agreement between ATHX and FDA on the trial protocol and end points. If it is, the trial will be very interesting in that it is going to be short. Less than a day after application, they will know if the treatment has worked or not. They will watch the patient for a few days more until there are no more changes and also to accumulate data. Depending on the number of patients agreed to for the trial, it could end in 6 months or less. This is going to be exciting to watch.
    Sep 17, 2015. 01:29 PM | 2 Likes Like |Link to Comment
  • Coming Around (A Bit) On MagicJack VocalTec  [View article]
    Furthermore, I find it really convenient with the apps installed in my iPad mini which I use a lot to take pictures and for emails. I made a trip to Canada recently and was able to talk to my friends in the US where ever there was wifi.... which was easy to find.
    Sep 15, 2015. 10:42 AM | 1 Like Like |Link to Comment
  • Ocata Therapeutics: Are You Watching A Bluebird Go By?  [View article]
    If I may add to your reasoning, the Safety trial is done so two eyes will be safe to do together. In addition, the FDA will want to find out what happens when two eye are treated.... which is the ultimate goal. I believe AMD and SMD happen to both eyes together with a variation in degree of deterioration.
    Sep 10, 2015. 12:01 PM | 1 Like Like |Link to Comment
  • Ocata Therapeutics: Are You Watching A Bluebird Go By?  [View article]
    Wotton did mention in I believe the 1st QTR C. that the vision improvement in all trial patients continues to hold. This implies that the 1st person to be treated with only 50,000 cells is still benefiting...4/5 years later.

    You mentioned that a re-treatment may be needed since one treatment may not last. It is possible. but the fact that OCAT is raising the dose to 300-400K could mean they are injecting enough cells to replace all the bad cells in the macula and because they are hESC cells (baby) they should last as long as the patient is alive.

    I do not know how many cells a typical macula has but I would think OCAT scientists would want to inject more than enough cells to insure all bad cells can and will be replaced to make vision restoration possible. Any excess cells will be naturally drain out of the eye.
    Sep 10, 2015. 11:40 AM | 1 Like Like |Link to Comment
  • Ocata Therapeutics: Are You Watching A Bluebird Go By?  [View article]
    hmleod -- thanks for posting. This is quite a read but very educational and I can say that my knowledge of OCAT's venture in HMC's/treatment for Lupus has just jumped 10,000%!
    Sep 10, 2015. 11:17 AM | 1 Like Like |Link to Comment
  • Sirius XM +1.3%, adds $2B in buyback authorization, to total $8B  [View news story]
    SIRI is taking advantage of the very low interest available today before the FED raises the interest rate, to buy back shares at today's relatively low prices. Bottom line is SIRI saves a lot of money by borrowing instead of using their cash on hand. A couple of years from now, when the interest rates are much higher, SIRI will then pay off its loans with cash on hand.
    Aug 26, 2015. 04:50 PM | 2 Likes Like |Link to Comment
  • Why I Think InVivo Shares Are Worth A Double  [View article]
    We have hundreds of thousands of people who had accidents over many decades that fit the NVIV criteria. They did not get any treatment (noe available until now) and the results are all on record. No need to have new controls.
    Aug 20, 2015. 03:43 PM | 1 Like Like |Link to Comment
  • Why I Think InVivo Shares Are Worth A Double  [View article]
    #3 got treated today. Sept 30 we will know his progress.
    Aug 20, 2015. 03:38 PM | Likes Like |Link to Comment
  • A Case For Ocata Therapeutics  [View article]
    Where did you get your information on the OCATA trials from? Looks like you did not do proper due diligence or did not understand the past results of the trials. Coming from an Opthalmologist..... if I had a problem with my eyes, I assure you, I will not come to you for treatment.
    Aug 20, 2015. 02:47 AM | 2 Likes Like |Link to Comment
  • Ocata Therapeutics: Insider Enrichment, Failed Science, Long History Of Fraud Ties, 77% Downside  [View article]
    To be able to borrow money, a company has to show it can pay it back. OCAT got the money today ($7 Million) so the lender is confident OCAT is a viable company!
    Aug 19, 2015. 01:41 PM | 7 Likes Like |Link to Comment
  • Ocata Therapeutics: Insider Enrichment, Failed Science, Long History Of Fraud Ties, 77% Downside  [View article]
    It appears that the author's intent in writing this article is to bring down OCAT. I think most investors who have read this piece have seen this, hence, the share is up 6%.
    Aug 19, 2015. 01:33 PM | 11 Likes Like |Link to Comment
  • Ocata Therapeutics: Insider Enrichment, Failed Science, Long History Of Fraud Ties, 77% Downside  [View article]
    Furthermore. the author has shown his selective use of information to support his arguments. He ignores the fact that OCAT's CEO had explained at the last two Quarterly Conference Calls, that the upcoming Ph 2 Trials will have Blind (no pun intended) Placebo patients - half will get the treatment, the other half will get a placebo treatment only. ( I feel bad that these people's eyes will continue to deteriorate and have zero chance of seeing better unless the trial is so successful, they will be given the treatment too, and hopefully by then it is not too late.) Then some will get immune suppressants and some will not to determine if it is needed or not.
    Aug 19, 2015. 01:29 PM | 9 Likes Like |Link to Comment
  • Ocata Therapeutics: Insider Enrichment, Failed Science, Long History Of Fraud Ties, 77% Downside  [View article]
    This article is full of false information.

    Start with trial record of 12 months monitoring only.
    The first patient was injected with 50,000 cell dosage in 2010.... more than 5 years ago and no evidence of tumor or cell turning into bones or other type of cells. First patient was so successful the she wants her "control" eye to be treated too but to date, OCAT refuses.

    "This is not a typo: There were only 4 patients in the study."
    42 patients have been treated as of last year in the Ph 1/2a Trial.

    There are more falsehoods.... this is so bad I do not know why I am even making comments here and just wasting my time and raising my blood pressure.
    Aug 19, 2015. 01:02 PM | 24 Likes Like |Link to Comment
  • A Case For Ocata Therapeutics  [View article]
    OCAT just announced this morning that they raised $10 funding. No mention of selling securities (dilution). But they just sold $30million, what is going on? JMY - what does this men, more dilution,
    Aug 19, 2015. 09:43 AM | Likes Like |Link to Comment
  • OK, I'll Say It: Sirius XM Had A Great Quarter  [View article]
    The article 'Why I Sold Sirius XM After Earnings for Zero Gain' main theme was that AT&T was getting into the connected car business big time and was therefore going to wipe out SIRI XM. A reader commented that the argument had a serious flaw because that connected car business was a collaboration between AT&T and SIRI and provided a link to a long article that discussed at length the joint venture. For some reason Seeking Alpha took out those comments.
    Aug 17, 2015. 01:08 PM | 4 Likes Like |Link to Comment
COMMENTS STATS
429 Comments
723 Likes